Abstract
Anandamide (20:3, n − 6) (homo-γ-linolenylethanolamide) and anandamide (22:4, n − 6) (7,10,13,16-docosatetraenylethanolamide) are known to be present in porcine brain and to undergo specific binding to cannabinoid binding sites. We have now shown that both compounds inhibit the electrically evoked twitch response of the mouse isolated vas deferens (IC 50 = 99.3 and 95.5nM respectively) indicating that they also have the ability to elicit a response. As electrically evoked contractions of the mouse vas deferens are also inhibited by the endogenous cannabinoid, anandamide (20:4, n − 6) (arachidonylethanolamide; IC 50 = 52.7 nM ), and by other cannabinoids, we conclude that anandamide (20:3, n − 6) and (22:4, n − 6), may, together with anandamide (20:4, n − 6), serve as endogenous cannabinoid receptor agonists. This conclusion is supported by our other main finding, that vasa deferentia show tolerance to the inhibitory effects of anandamide (20:3, n − 6) and anandamide (22:4, n − 6) when obtained from mice subjected to a Δ 9-tetrahydrocannabinol pretreatment that is known to induce cannabinoid tolerance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
